Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression
NCT ID: NCT04359745
Last Updated: 2023-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2019-03-21
2025-05-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If doctors mistake the appearance of treatment side-effects for growing cancer, they may think that the treatment is failing and change the patient's treatment too early or put them into a clinical trial. This means that patients may not be given the full treatment and the results from some clinical trials cannot be trusted.
The aim of this study is to provide doctors with a computer program that will use MRI images of the brain that are routinely obtained throughout treatment, in order to help them more accurately identify when the cancer regrows.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
NCT00001148
Intraoperative Hyperspectral Imaging for Fluorescence Guided Surgery in Low Grade Gliomas
NCT05397574
Discerning Pseudoprogression vs True Tumor Growth in GBMs
NCT02905643
Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)
NCT03294434
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
NCT04143425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data collected at KCH from the last 24 months shows that, even at a leading glioma imaging centre, only 66% of patients had advanced imaging (e.g. DSC-MRI) performed at the time of increase in contrast-enhancement i.e. possible progression. The primary aim of this research is to use routine clinical MRI data in order to train the classifier. This will increase the utility of the classifier, as such routine MRI data can be acquired by all imaging centres, and the new classifier can therefore provide a much more cost-efficient solution than an alternative classifier which may depend on advanced imaging techniques.
Initial training, testing and cross validation of a classification model will be carried out using MRI data of glioblastoma obtained from publicly-accessible imaging archives and King's College Hospital (KCH), London. For clinical validation, the trained model will undergo testing using MRI data from patients recruited prospectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient undergoing the standard Stupp treatment regimen
* Have had a pre-surgery scan and at least one follow-up scan post-chemoradiation
Exclusion Criteria
* The patient's treatment deviates greatly from the standard Stupp regimen, such as they are recruited into interventional trials and sufficient information is not known about the patient's trial treatment
* Patients receiving treatment with Angiogenesis inhibitors such as bevacizumab prior to completion of the Stupp regimen
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King's College London
OTHER
Guy's and St Thomas' NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Booth
Role: PRINCIPAL_INVESTIGATOR
King's College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust
Brighton, , United Kingdom
Velindre Cancer Centre, Velindre University NHS Trust
Cardiff, , United Kingdom
Ninewells Hospital and Medical School, NHS Tayside
Dundee, , United Kingdom
Hull Royal Infirmary, Hull University Teaching Hospitals NHS Trust
Hull, , United Kingdom
Leeds General Infirmary, The Leeds Teaching Hospitals NHS Trust
Leeds, , United Kingdom
Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust
London, , United Kingdom
King's College Hospital, King's College Hospital NHS Trust
London, , United Kingdom
Charing Cross Hospital, Imperial College Healthcare NHS Trust
London, , United Kingdom
National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust
London, , United Kingdom
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, , United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust- Newcastle Freeman Hospital
Newcastle, , United Kingdom
Nottingham University Hospitals NHS Trust- City Hospital
Nottingham, , United Kingdom
University Hospitals Plymouth NHS Trust
Plymouth, , United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, , United Kingdom
The Royal Marsden Hospital, Royal Marsden NHS Foundation Trust
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5.0 15/01/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.